The currency market is still taking its clues from the equity market changes as a mirror of the current financial markets turmoil. The markets eyes were looking for what can be for Citigroup not just these recent days which had a massive selling of the stock but may be since the bankruptcy of Lehman Brothers. The market has looked at the rescue plan of citi as a turning point of the crisis itself even if there are others in need of similar stimulus huge bailing out plans as the markets were looking at the spreading out group across the broad as very big to be allowed to fall with more than 2$ trillions of assets. The market has reacted strongly to the news and pushed the Japanese yen lower across the broad and the greenback in a sign of confidence in the equity markets to take risks again away from the current safe haven stance in the markets which pushed the gold prices recently above 800$, In spite of the current decline of inflation rates around the globe as a negative impact of outlook of the recession which resulted from the financial crisis. God willing, The gold will face serious pressure at these levels right now and in the coming few days by the thanks giving holidays which can calm down the market volumes.

Labopharm announces that its trazodone API supplier has resolved outstanding manufacturing issues with the FDA

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has been informed by Angelini, the manufacturer of the active pharmaceutical ingredient (API) for the Company's novel trazodone formulation, that it has received a letter from the U.S. Food and Drug Administration (FDA) stating that Angelini has appropriately addressed all deficiencies cited by the FDA following its inspection of the manufacturing facility in June and July of this year. The letter further states that Angelini's manufacturing facility has been classified as acceptable.

Labopharm received a complete response letter from the FDA on July 17, 2009 indicating the Company's new drug application (NDA) for its novel trazodone formulation could not be approved in its present form due to the deficiencies at the API supplier's manufacturing facility. The letter did not raise any efficacy or safety issues.